Shanghai JMT-Bio
CompanyChina
Shanghai JMT-Bio develops one asset, approved (semaglutide in cardiovascular disease). Mostly peptide acting on Insulin/IGF-1 signalling, lipid and ceramide metabolism and GLP1R; based in China.
- Assets
- 1
- Furthest
- Approved
- Trials
- 9
- Signals
- 2
Pipeline
1GLP-1 receptor agonist
ApprovedPeptideInsulin/IGF-1 signallingLipid and ceramide metabolismcardiovascular diseasechronic kidney disease
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms5
- Trials10
- Signals5
- Similar companies6
Updated 7 Oct 2026 · 65 sources